NCT03066206 2026-02-20
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC
M.D. Anderson Cancer Center
Phase 2 Terminated
Clinical Trials
8 trialsNCT05045404 2023-09-13
Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03292250 2022-03-29
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
Phase 2 Completed
NCT02544997 2020-07-07
A Phase II, Single-Arm Trial of Poziotinib as Salvage Treatment in Patients With Metastatic Breast Cancer Who Has HER2 or EGFR Mutation or Activated AR or EGFR Pathway
Samsung Medical Center
Phase 2 Completed
NCT02216916 2019-03-18
Phase II Trial of HM781-36B in Patients With Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) After Failure of or Unfit for Platinum-containing Therapy
Yonsei University
Phase 2 Unknown
NCT03770988 2019-02-22
A Trial to Evaluate the Efficacy of Poziotinib, Pan HER Inhibitor in Recurrent/Metastatic Esophageal Cancer (R/M ESCC)
Yonsei University
Phase 2 Unknown
NCT02979821 2018-05-24
Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)
Korean Association for the Study of Targeted Therapy
Phase 2 Completed
NCT01819428 2016-03-01
NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma
National OncoVenture
Phase 2 Terminated